2. Search Result
Search Result
Isoforms Recommended: MNK1
Results for "

Mnk1

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Natural
Products

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139684
    MNK1/2-IN-5

    		MNK Infection Inflammation/Immunology Cancer
    MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor as a therapeutic agent.
    MNK1/2-IN-5
  • HY-148105
    DS12881479

    		MNK Cancer
    DS12881479 is a potent and selective Mnk1 inhibitor with an IC50 value of 21 nM. DS12881479 can be used in cancer research [1].
    DS12881479
  • HY-112424
    Tinodasertib
    1 Publications Verification

    ETC-206

    		 MNK Cancer
    Tinodasertib (ETC-206) is a selective MNK1 and MNK2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
    Tinodasertib
  • HY-112113
    SLV-2436

    SEL201-88; SEL-201

    		 MNK Cancer
    SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8  nM and 5.4 nM, respectively.
    SLV-2436
  • HY-10520
    CGP 57380
    4 Publications Verification

    		 MNK Apoptosis Cancer
    CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.
    CGP 57380
  • HY-146735
    MNK1/2-IN-6

    		MNK Apoptosis Cancer
    MNK1/2-IN-6 is a potent and selective MNK1/2 inhibitor with IC50s of 2.3 nM and 3.4 nM for MNK1 and MNK2, respectively. MNK1/2-IN-6 induces apoptosis in a concentration-dependent manner [1].
    MNK1/2-IN-6
  • HY-158438
    MNK1/2-IN-8

    		MNK Cancer
    MNK1/2-IN-8 (compound 15b) is a MNK1/2 inhibitor with the IC50 values of 0.8 and 1.5 nM against Mnk1 and Mnk2. MNK1/2-IN-8 shows anti-proliferative activity and induces cell cycle arrest [1].
    MNK1/2-IN-8
  • HY-163479
    MNK1/2-IN-7

    		Eukaryotic Initiation Factor (eIF) MNK Cancer
    MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970) [1].
    MNK1/2-IN-7
  • HY-124638
    MNK inhibitor 9

    		MNK Cancer
    MNK inhibitor 9 is a potent and selective inhibitor of MNK1/2 with IC50 values of 0.003 µM and 0.003 µM for MNK1 and MNK2 respectively. MNK inhibitor 9 has good cell permeability. MNK inhibitor 9 can be used in tumor related research [1].
    MNK inhibitor 9
  • HY-156511
    ETC-168

    		MNK Cancer
    ETC-168 is a selective and oral active MNK inhibitor with the IC50 values of 23 and 43 nM against MNK1 and MNK2, respectively. ETC-168 shows antiproliferative efficacy in vivo and in vitro [1].
    ETC-168
  • HY-131249
    MK2-IN-3
    2 Publications Verification

    		 MAPKAPK2 (MK2) Inflammation/Immunology
    MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo [1].
    MK2-IN-3
  • HY-146805
    EB1

    		MNK Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation [1] .
    EB1
  • HY-100022A
    Tomivosertib hydrochloride

    eFT508 hydrochloride

    		 MNK PD-1/PD-L1 Cancer
    Tomivosertib hydrochlorideis a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib hydrochloride treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines [1]. Tomivosertib hydrochloride also dramatically downregulates PD-L1 protein abundance .
    Tomivosertib hydrochloride
  • HY-100022
    Tomivosertib
    Maximum Cited Publications
    10 Publications Verification

    eFT508

    		 MNK PD-1/PD-L1 Cancer
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines [1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
    Tomivosertib
  • HY-112457
    MK2-IN-3 hydrate
    2 Publications Verification

    		 MAPKAPK2 (MK2) Inflammation/Immunology
    MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 [1].
    MK2-IN-3 hydrate
  • HY-150612
    (R)-STU104

    		p38 MAPK Cancer
    (R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis [1].
    (R)-STU104
  • HY-124645
    QL-X-138

    		Flavivirus Dengue virus Btk MNK Infection Cancer
    QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies [1] .
    QL-X-138
  • HY-N3127
    Orobol

    		Casein Kinase PI3K VEGFR Metabolic Disease
    Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ) [1] .
    Orobol
  • HY-160777
    VNPP433-3β

    Galeterone 3β-imidazole

    		 Androgen Receptor MNK Cancer
    VNPP433-3β is a molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β inhibits proliferation of cancer cell LNCaP, C4-2B and CWR22Rv1 with GI50 of 0.2, 0.3 and 0.31 μM. VNPP433-3β exhibits good pharmacokinetic characters in CD-1 mouse and inhibits tumor growth in the CWR22Rv1 xenograft mouse model [1].
    VNPP433-3β

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: